ZA202212502B - Pharmaceutical composition comprising l-triiodothyronine (t3) for use in the treatment of tissue hypoxia and sepsis - Google Patents
Pharmaceutical composition comprising l-triiodothyronine (t3) for use in the treatment of tissue hypoxia and sepsisInfo
- Publication number
- ZA202212502B ZA202212502B ZA2022/12502A ZA202212502A ZA202212502B ZA 202212502 B ZA202212502 B ZA 202212502B ZA 2022/12502 A ZA2022/12502 A ZA 2022/12502A ZA 202212502 A ZA202212502 A ZA 202212502A ZA 202212502 B ZA202212502 B ZA 202212502B
- Authority
- ZA
- South Africa
- Prior art keywords
- triiodothyronine
- sepsis
- treatment
- pharmaceutical composition
- tissue hypoxia
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GR20200100200A GR1010068B (el) | 2020-04-21 | 2020-04-21 | Φαρμακευτικη συνθεση που περιεχει l-τριιωδοθυρονινη (τ3) για χρηση στη θεραπεια ασθενων σε κρισιμη κατασταση με λοιμωξη απο κορωνοϊο |
| GR20200100695A GR1010182B (el) | 2020-11-23 | 2020-11-23 | Φαρμακευτικη συνθεση που περιεχει l-τριιωδοθυρονινη (τ3) για χρηση στην αντιμετωπιση της ιστικης υποξιας |
| GR20210100216A GR1010261B (el) | 2021-03-29 | 2021-03-29 | Φαρμακευτικη συνθεση που περιεχει l-τριιωδοθυρονινη (τ3) για χρηση στην αντιμετωπιση της φλεγμονωδους αντιδρασης και της δυσλειτουργιας του καρδιαγγειακου συστηματος λογω σηψης |
| PCT/GR2021/000019 WO2021214497A1 (en) | 2020-04-21 | 2021-04-15 | Pharmaceutical composition comprising l-triiodothyronine (t3) for use in the treatment of tissue hypoxemia and sepsis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202212502B true ZA202212502B (en) | 2024-05-30 |
Family
ID=76197481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2022/12502A ZA202212502B (en) | 2020-04-21 | 2022-11-16 | Pharmaceutical composition comprising l-triiodothyronine (t3) for use in the treatment of tissue hypoxia and sepsis |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230157982A1 (https=) |
| EP (1) | EP4138810A1 (https=) |
| JP (1) | JP2023538984A (https=) |
| KR (1) | KR20230022839A (https=) |
| CN (1) | CN115996710B (https=) |
| AU (1) | AU2021258544A1 (https=) |
| BR (1) | BR112022021250A2 (https=) |
| CA (1) | CA3176106A1 (https=) |
| GE (2) | GEP20247706B (https=) |
| IL (1) | IL297398B1 (https=) |
| MX (1) | MX2022013228A (https=) |
| WO (1) | WO2021214497A1 (https=) |
| ZA (1) | ZA202212502B (https=) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1942995A (en) * | 1994-03-15 | 1995-10-03 | K.U. Leuven Research & Development | New use of growth hormone |
| SI3908272T1 (sl) | 2019-01-09 | 2023-07-31 | Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. | L-trijodotironin (t3) za uporabo pri omejevanju mikrovaskularne obstrukcije |
-
2021
- 2021-04-15 CA CA3176106A patent/CA3176106A1/en active Pending
- 2021-04-15 KR KR1020227039203A patent/KR20230022839A/ko active Pending
- 2021-04-15 JP JP2022563957A patent/JP2023538984A/ja active Pending
- 2021-04-15 CN CN202180029865.9A patent/CN115996710B/zh active Active
- 2021-04-15 IL IL297398A patent/IL297398B1/en unknown
- 2021-04-15 GE GEAP202116094A patent/GEP20247706B/en unknown
- 2021-04-15 WO PCT/GR2021/000019 patent/WO2021214497A1/en not_active Ceased
- 2021-04-15 AU AU2021258544A patent/AU2021258544A1/en active Pending
- 2021-04-15 EP EP21728969.3A patent/EP4138810A1/en active Pending
- 2021-04-15 MX MX2022013228A patent/MX2022013228A/es unknown
- 2021-04-15 BR BR112022021250A patent/BR112022021250A2/pt unknown
- 2021-04-15 US US17/920,171 patent/US20230157982A1/en active Pending
- 2021-04-15 GE GEAP202416094A patent/GEAP202416094A/en unknown
-
2022
- 2022-11-16 ZA ZA2022/12502A patent/ZA202212502B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023538984A (ja) | 2023-09-13 |
| IL297398A (en) | 2022-12-01 |
| WO2021214497A1 (en) | 2021-10-28 |
| MX2022013228A (es) | 2022-11-14 |
| GEP20247706B (en) | 2024-12-10 |
| CA3176106A1 (en) | 2021-10-28 |
| AU2021258544A1 (en) | 2022-10-27 |
| IL297398B1 (en) | 2026-01-01 |
| BR112022021250A2 (pt) | 2022-12-06 |
| EP4138810A1 (en) | 2023-03-01 |
| GEAP202416094A (en) | 2024-07-10 |
| CN115996710A (zh) | 2023-04-21 |
| CN115996710B (zh) | 2024-06-28 |
| KR20230022839A (ko) | 2023-02-16 |
| US20230157982A1 (en) | 2023-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3788047T3 (fi) | Fgft-estäjän kiinteitä muotoja ja menetelmiä niiden valmistamiseksi | |
| EA202190567A1 (ru) | Специальные комбинированные композиции ингаляционного нинтеданиба и солей нинтеданиба | |
| WO2009039992A3 (en) | Use of band 3 protein (824-829) and/or melanocyte-stimulating hormone release-inhibiting factor as a therapeutic agent in the treatment of pseudomonas aeruginosa infection | |
| WO2009043448A3 (en) | Neuromedin u-25 and neuromedin s as therapeutic agents | |
| WO2009040069A3 (en) | Use of bq-610 alone or in combination with helodermin as a therapeutic agent | |
| WO2009033792A3 (en) | Gamma 1 msh alone or in combination with pentagastrin as a therapeutic agent | |
| WO2009040036A3 (en) | Use of a galanin peptide as a therapeutic agent | |
| WO2009033661A3 (en) | Use of rgdspasskp and optionally angiotensin ii as therapeutic agents in the treatment of eg s. pneumoniae infections | |
| WO2009046845A3 (en) | Use of a lactoferrin partial peptide peptide as a therapeutic agent | |
| WO2009039973A3 (en) | Use of peptide arg-asn-ile-ala-glu-ile-ile-lys-asp-ile-oh or its combination with the peptide asp-arg-gly-asp-ser-oh as a therapeutic agent | |
| WO2009043454A3 (en) | Use of pacap-27 as a therapeutic agent | |
| WO2009040051A3 (en) | Use of the peptide rfmwmk alone or in combination with the peptide ymdgtmsqv as a therapeutic agent | |
| WO2009039986A3 (en) | Use of the peptide asn-asp-asp-cys-glu- leu-cys-val-asn-val-ala-cys-thr-gly-cys-leu alone or in combination with the peptide thr-thr-ser-gln-val- arg-pro-αrg as a therapeutic agent | |
| RU2019140862A (ru) | Варианты сульфамидазы (sgsh), векторы, композиции и способы, и применения для лечения мукополисахаридоз типа iiia (mps iiia) | |
| FI4009978T3 (fi) | Sepiapteriiinin ja sen metaboliittien käyttö säteilyaltistuksen hoitoon | |
| EA201390720A1 (ru) | Способы улучшения оксигенации ткани, подвергающейся опасности | |
| RU2018107930A (ru) | Агонисты tlr4, их композиции и применение для лечения рака | |
| FI3565551T3 (fi) | Menetelmiä bakteeri-infektioiden hoitamiseksi vaborbaktaamin ja meropeneemin yhdistelmällä | |
| ZA202212502B (en) | Pharmaceutical composition comprising l-triiodothyronine (t3) for use in the treatment of tissue hypoxia and sepsis | |
| BRPI0412453A (pt) | uso do ácido ascórbico ou um sal fisiologicamente aceitável do mesmo | |
| JP2007504194A5 (https=) | ||
| WO2020068657A8 (en) | 2'-halogenated-4'-thio-2'-deoxy-5-azacytidine analogs and use thereof | |
| RU2010129409A (ru) | Способ лечения псороптоза кроликов и отодектоза плотоядных животных | |
| EA202192234A1 (ru) | Комбинированная терапия для применения в лечении рака | |
| AR129944A1 (es) | Uso de compuestos que contienen manganeso para reducir el nivel de ácido úrico en sujetos mamíferos; una composición; un kit y un método de prevención y/o tratamiento |